Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Corcept Therapeutics is a commercial-stage pharmaceutical company focused on cortisol modulation, with its flagship product Korlym (mifepristone) approved for Cushing's syndrome treatment generating approximately $700M in annual revenue. The company operates as a specialty pharmaceutical with a single marketed asset while advancing a pipeline of selective cortisol modulators targeting larger indications including antipsychotic-induced weight gain and ovarian cancer. Recent 45%+ stock decline reflects pipeline setbacks and competitive concerns despite strong underlying commercial fundamentals.
Corcept generates revenue through direct sales of Korlym to a small, well-defined patient population with endogenous Cushing's syndrome, a rare endocrine disorder affecting approximately 20,000 diagnosed patients in the US. The company maintains exceptional pricing power due to orphan drug exclusivity (expires 2032), limited competition, and high unmet medical need, with annual treatment costs exceeding $200,000 per patient. The 98.4% gross margin reflects minimal manufacturing costs for a small-molecule drug with established supply chains. Commercial strategy focuses on direct physician engagement with endocrinologists and expanding diagnosis rates in the undertreated Cushing's population. Pipeline value centers on relacorilant, a next-generation selective cortisol modulator with potentially broader applications and improved side effect profile compared to mifepristone.
Relacorilant clinical trial readouts and FDA regulatory milestones for antipsychotic-induced weight gain and ovarian cancer indications
Korlym quarterly prescription volume trends and revenue growth trajectory relative to 20,000-patient diagnosed population ceiling
Competitive threats from generic mifepristone entrants or alternative cortisol modulators in development
Pipeline expansion announcements and partnership deals for selective cortisol modulator platform
Patent litigation outcomes affecting Korlym exclusivity period extending beyond 2032
Orphan drug exclusivity expiration in 2032 opens Korlym to generic competition, with mifepristone being off-patent and relatively simple to manufacture, potentially eroding 100% of current revenue base without successful pipeline diversification
Regulatory pathway uncertainty for cortisol modulators in broader indications beyond rare diseases, with FDA requiring large-scale safety databases given mifepristone's mechanism and historical controversy
Reimbursement pressure on high-cost specialty drugs as payers implement stricter utilization management and outcomes-based contracting requirements
Multiple companies developing alternative cortisol modulators (Xeris Pharmaceuticals' relacorilant biosimilar threats, Strongbridge's levoketoconazole) targeting same Cushing's population with potentially superior safety profiles
Large pharmaceutical companies entering cortisol modulation space for high-prevalence indications like metabolic syndrome or psychiatric disorders, leveraging greater commercial scale
Generic mifepristone manufacturers challenging patents or seeking abbreviated approval pathways ahead of 2032 exclusivity expiration
Limited near-term balance sheet risk given strong cash position and cash generation, but extended pipeline development timelines could pressure liquidity if Korlym growth stalls
Equity dilution risk if relacorilant Phase 3 programs require additional capital raises, particularly if market conditions remain unfavorable for biotech financing
low - Specialty pharmaceutical treating serious endocrine disorder demonstrates minimal GDP sensitivity. Cushing's syndrome patients require treatment regardless of economic conditions, and high-cost therapies are typically covered by commercial insurance or Medicare with limited out-of-pocket exposure. However, moderate sensitivity exists through diagnostic rates, as economic downturns may reduce routine healthcare visits where Cushing's is identified, and payer budget pressures could affect prior authorization approval rates.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for pre-revenue pipeline assets, particularly impacting biotech stocks trading on long-dated cash flow expectations from relacorilant commercialization post-2027; (2) Increased financing costs affect capital allocation decisions for clinical trial investments, though Corcept's $600M+ cash position and positive operating cash flow minimize near-term funding concerns. The 56x EV/EBITDA multiple reflects significant rate sensitivity as investors reassess risk-adjusted returns.
Minimal - Company maintains fortress balance sheet with 0.01 debt-to-equity ratio, $600M+ cash, and positive free cash flow generation. No meaningful credit facility dependence or refinancing risk. Customer credit exposure is negligible as revenue flows through specialty pharmacy distributors and government/commercial payers with high creditworthiness.
growth - Stock attracts growth-oriented biotech investors focused on pipeline optionality and commercial-stage de-risking. The 40% revenue growth, expanding margins, and multiple Phase 3 catalysts appeal to investors seeking asymmetric upside from successful relacorilant launches in multi-billion dollar markets (antipsychotic-induced weight gain affects 3M+ patients). However, recent 45% drawdown has introduced value characteristics with 5.6x P/S multiple below historical biotech comps, attracting contrarian investors betting on pipeline recovery. Minimal dividend yield (company retains cash for R&D) limits income investor appeal.
high - Single-product commercial model with binary pipeline catalysts creates significant event-driven volatility. Stock exhibits elevated beta typical of mid-cap biotech (estimated 1.5-2.0x) with sharp moves on clinical trial readouts, FDA decisions, and competitive developments. Recent 45% decline demonstrates downside volatility from pipeline setbacks. Limited institutional ownership diversification and modest trading liquidity amplify price swings around catalysts.
